Biogen price target lowered to $250 from $260 at BofA

BofA lowered the firm’s price target on Biogen to $250 from $260 and keeps a Neutral rating on the shares after updating the firm’s model to reflect Q1 results. The firm now forecasts $9.5B in revenue and $15.10 in EPS for 2024.